Gain Therapeutics (GANX) Stock Overview
A biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GANX Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Gain Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.84 |
| 52 Week High | US$4.34 |
| 52 Week Low | US$1.41 |
| Beta | 0.11 |
| 1 Month Change | -34.98% |
| 3 Month Change | -20.35% |
| 1 Year Change | 16.46% |
| 3 Year Change | -61.43% |
| 5 Year Change | -86.95% |
| Change since IPO | -83.57% |
Recent News & Updates
Recent updates
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients
Nov 07Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Dec 31Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
May 29Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Jan 12Gain Therapeutics appoints CEO
Sep 20Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Oct 27Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Aug 19Shareholder Returns
| GANX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.5% | 1.6% | 3.4% |
| 1Y | 16.5% | 46.8% | 29.7% |
Return vs Industry: GANX underperformed the US Biotechs industry which returned 41.7% over the past year.
Return vs Market: GANX underperformed the US Market which returned 25.7% over the past year.
Price Volatility
| GANX volatility | |
|---|---|
| GANX Average Weekly Movement | 16.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: GANX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GANX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 21 | Gene Mack | gaintherapeutics.com |
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company’s lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s disease with or without a GBA1 mutation.
Gain Therapeutics, Inc. Fundamentals Summary
| GANX fundamental statistics | |
|---|---|
| Market cap | US$76.04m |
| Earnings (TTM) | -US$20.16m |
| Revenue (TTM) | n/a |
Is GANX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GANX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$10.07m |
| Gross Profit | -US$10.07m |
| Other Expenses | US$10.09m |
| Earnings | -US$20.16m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.2% |
How did GANX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 17:56 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gain Therapeutics, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Thomas Shrader | BTIG |
| Raghuram Selvaraju | H.C. Wainwright & Co. |